All News

back, LBP, spine, AS

Can Rheumatologists Accurately Diagnose axSpA in Patients with Chronic Back Pain?

d Sheila Reyes, MD

Chronic low back pain is a common complaint that brings patients to the doctor’s attention. Although the majority of low back pain is mechanical in nature, an important minority is inflammatory in nature.

Read Article
Rheumatology,Roundup,2023

Rheumatology Roundup - ACR 2023

d Jack Cush, MD

Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.

Read Article
ACR Best

#ACRbest Abstracts – Day 4

d Jack Cush, MD

While there wasn’t much original new programming and research presented on the final day, that didn’t slow the RheumNow faculty from tweeting the noteworthy “Best of ACR” abstracts. Enjoy these below.

Read Article
lupus SLE

The impact of SGLT2-inhibitor on SLE outcomes

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

Since chronic kidney disease is one of the strongest CV risk factors, any new strategy to reduce proteinuria and avoid a decline in renal function may likely improve patient outcomes. In large cardiovascular outcome trials, the use of a fairly new-kid-on-the-block therapy, sodium–glucose cotransporter-2 inhibitors (SGLT2i) appear to be both cardio and renal-protective. Would the use of SGLT2i have the same impact in SLE?

Read Article
meeting.audience.3_0.jpg

ACR 2023 – Day 4 Report

d Jack Cush, MD

The last day at ACR23 was a ghost town as most left, largely because there was limited programming on the fourth and final day. The main attraction on Day 4 was the late-breaking abstract – oral presentations.  Here’s a list of the late breakers; below, I provide commentary on the ones that caught my attention.

Read Article
New Biomarkers and Therapeutics Show Potential in Still's Disease AOSD is a rare complex, sporadic, systemic autoinflammatory disease similar to sJIA characterized by sustained fever, salmon-colored rash, and arthritis https://t.co/cGBBHsBdK7 https://t.co/a0EwBiTJSu

Links:

Dr. John Cush RheumNow ( View Tweet)
Urinary biomarkers precede loss of kidney function for lupus nephritis In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation. https://t.co/MJb9F3uEgr https://t.co/oXvNLelE89

Links:

Dr. John Cush RheumNow ( View Tweet)
Less (Glucocorticoids) is More in Lupus Nephritis Dr. Yuz Yusof talks with Dr. Amir Saxena about abstract 0781 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/EriaJvBPj9 https://t.co/x5hNIAgBz2

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult toTreat PsA: Mainly Difficult to Define! Dr. Aurelie Najm reports on abstract 0777 from the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/vXDY47xWfS https://t.co/l5hJFc7blH

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis Topic Panel https://t.co/I3puVr5HWa https://t.co/sCzjnnDG1G

Links:

Dr. John Cush RheumNow ( View Tweet)
Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology The top ACR2023 Plenary abstracts Dr. Dao ( @kdao2011) found impactful for her practice were... https://t.co/aXut7l7b79 https://t.co/ATO5r5OzGK

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR23 – Day 3 Report F2F learning amidst miles of research and many young talented aside wizened establish presenters is such a welcome return to ACR, the way it should be. https://t.co/TwmwfEQZdp https://t.co/Yo27c7ig8N

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Lupus Nephritis Therapy Paradigm Shift Dr. Yuz Yusof reporting on abstract 0782 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/poIVX74EnO https://t.co/tWlRlwTfH0

Links:

Dr. John Cush RheumNow ( View Tweet)
IV Secukinumab for AxSpa The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. https://t.co/eDAWevPLkE https://t.co/AlWYGAQP5T

Links:

Dr. John Cush RheumNow ( View Tweet)
Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA Dr. Robert Chao (Tysons, VA) discusses Abstract 0522 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/UmcbplfGhB https://t.co/R5Lr6Q0qHI

Links:

Dr. John Cush RheumNow ( View Tweet)
How early is early in psoriatic arthritis? Is there a window of opportunity for treatment in PsA to ensure optimal outcomes? https://t.co/SHA8Gdm1GD https://t.co/GbFfeB2Euw

Links:

Dr. John Cush RheumNow ( View Tweet)
Cancer and TNF inhibitors Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions https://t.co/MzksmSEUjf https://t.co/dxCIHxL1gc

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: SpA Insights: New Therapies https://t.co/01wwJIkmRJ https://t.co/tMJufATzyd

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACRbest Abstracts – Day 2 Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNows #ACRbest abstract reports from Monday, 11/13 at #ACR23. https://t.co/yIYYI7IVBD https://t.co/86Nt1mVha8

Links:

Dr. John Cush RheumNow ( View Tweet)
Monitoring the Effect of Upadacitinib Therapy with a Smart Watch? https://t.co/z6durHZ57R https://t.co/wSJiWNOx9M

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×